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Abstract  
Background 
 Colorectal cancer in pregnancy is a rare pathology with limited high-grade 
evidence available for guidance. The diagnosis of  CRC in pregnant women is usually 
delayed, and once diagnosis is made, challenges exist as treatment options may be 
limited.  
 
Objective 
 The study aims to highlight the importance of early investigation of 
symptomatic patients during pregnancy, as well as to update treatment and prognosis in 
CRC. 
 
Methods 
 A literature search in Pubmed database, including articles from 2006 to 2016 
and cross-research articles with the initial research. 
 
Results 
 Pregnancy can limit and contraindicate the utilization of standard diagnostic and 
therapeutic tools, which in particular can hamper the liberal use of colonoscopy and CT. 
Physical evaluation and abdominal US are first recommended; besides, MRI or CT may 
be used, only in indicated cases.  
 Surgery is the main stay of treatment but radiotherapy and chemotherapy have 
significant role in posterior management of tumour. 
 
Discussion 
 As abdominal symptoms are common in pregnancy and colorectal cancer can 
simulate them, the differential diagnosis between these two pathologies is crucial, since 
early interventions can be curative. 
 After diagnosis, the follow-up of pregnant women should be individualized, 
depending on several factors. However, since cancer treatment is currently possible in 
pregnancy, the patient's survival probability should not be decreased due to late 
diagnosis. 
 
Conclusions 
 Many studies are needed in order to achieve development in CRC pathogenesis 
during pregnancy as well as in treatment outcomes.  
 The potential curative treatment of the disease should be the main aim of 
treatment when considering CRC in pregnancy. However, it is crucial to adapt the 
treatment to each patient, taking into account conscious decision on pregnancy further 
management. 
 
Resumo 
Introdução 
 O cancro colorretal na gravidez é uma patologia rara, com limitada evidência 
científica para orientação terapêutica. O diagnóstico de cancro coloretal em mulheres 
grávidas é tardio e, quando o diagnóstico é feito, as opções de tratamento podem ser 
limitadas. 
 
Objetivo 
 O objetivo deste estudo é ressalvar a importância da investigação precoce de 
pacientes sintomáticas durante a gravidez, assim como avaliar os atuais métodos de 
tratamento e prognóstico no CCR. 
  
Métodos 
 A pesquisa bibliográfica foi realizada na base de dados PubMed, incluindo 
artigos a partir de 2006 até 2016, assim como artigos de pesquisa cruzada com os 
artigos iniciais. 
 
Resultados 
 A gravidez pode limitar e contra-indicar a utilização de ferramentas de 
diagnóstico e terapêuticas convencionais, assim como dificultar o uso indiscriminado de 
colonoscopia e tomografia computadorizada. A avaliação física e a ecografia abdominal 
são a primeira linha para diagnóstico. No entanto, em casos selecionados, a ressonância 
magnética ou a tomografia computadorizada também podem ser usadas. 
 A cirurgia é o gold-standard, mas a radioterapia e a quimioterapia assumem um 
papel cada vez mais relevante no tratamento multidisciplinar destes tumores. 
 
Discussão 
 Como os sintomas abdominais são comuns na gravidez e o cancro coloretal pode 
simulá-los, o diagnóstico diferencial entre estas duas patologias é crucial, já que 
intervenções precoces podem ser curativas. 
 Após diagnóstico, o seguimento das grávidas deve ser individualizado, 
dependendo de vários fatores. Porém, já que atualmente o tratamento do cancro é 
possível na gravidez, a probabilidade de sobrevivência da paciente não deve ser 
diminuída devido ao diagnóstico tardio. 
 
Conclusões 
 Outros estudos são ainda necessários para saber mais acerca da patogénese do 
cancro coloretal na gravidez, assim como os resultados após tratamento. 
 O potencial objetivo é o tratamento oncológico do cancro coloretal. No entanto, 
é crucial adaptar o tratamento a cada paciente, tendo em conta a sua decisão consciente 
acerca da continuação da gravidez. 
 Key-words 
Cancro do cólon; Cancro do reto; Gravidez; Diagnóstico do cancro; Tratamento do 
cancro. 
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Introduction 
Background 
 Colorectal cancer (CRC) in pregnancy is a condition that  represents a distinct 
entity from CRC in the general population, as it is a rare pathology with limited high-
grade evidence available for guidance. In fact, the literature on this subject is scant with 
fewer than 300 cases reported(1), which means there is limited experience on the 
management of CRC diagnosed during pregnancy.  
 The diagnosis of  CRC in pregnant women is usually delayed, because there is a 
significant overlap in signs and symptoms between a colorectal malignancy and normal 
pregnancy, impeding proper diagnosis(2–4). Once diagnosis is made, challenges exist as 
treatment options may be limited(2). That is why management requires judiciously 
individualized strategies after thorough patient counselling to deal with consequent 
emotional and physical stress, in order to ensure adequate psychological support and 
realistic expectations(2,5).
 
 
 The primary objective of this review was to highlight the importance of early 
investigation of symptomatic patients during pregnancy, as well as the role of 
chemotherapeutic, radiological and surgical interventions. Secondary objectives include 
a research about epidemiology of CRC during pregnancy, its implications  and 
prognostic features. 
 
Methods 
 The literature survey was conducted in Pubmed database. The words "colon 
pregnancy cancer" and "rectum pregnancy cancer" were used. Only the articles 
published from 2006 to 2016 were considered. After reading the title and abstract, and 
subject to an availability of the article, 31 articles were obtained in Pubmed. Articles 
obtained by cross-searching with the articles of the initial research with relevant 
information were also added. 
 
Results 
Epidemiology 
 CRC is the third most common type of cancer in women(4) with its highest 
incidence occurring in patients aged 50 years old(6); women older than 40 years tend to 
be 11 times more likely to develop CRC than those younger than 30 years of age(7,8). 
 While the overall incidence of CRC is steady or falling, some studies report an 
increased incidence of CRC in younger patients (< 40 years)(1), which means that 3% 
of patients with this cancer are younger than 40 years old(6). Nevertheless, for this age 
group, studies report that overall survival of CRC for women has improved 
substantially, with 5-year overall survival now approaching 80%(9). 
 Because of the increase in the incidence of CRC in younger patients, it may 
occur during the reproductive age, interfering with pregnancy(1). Cruveilhier reported 
the first case of rectal carcinoma in pregnancy in 1842, but now it is the seventh most 
common type of cancer in pregnancy(5,6). However, its incidence rate is controversial; 
some studies report an incidence of 0,002%(3,4,6–8,10,11) while others consider 0.07% 
to 0,1%(12–14), which means about 1 case per 13.000 gestations(3,5,15). The mean age 
of women with CRC during pregnancy has been reported as 31 years of age(4–6,16), 
with range of 16-48 years(12)
.
 
 Considering  racial predisposition, hispanic women were slightly less likely to 
develop CRC, in comparison with non-hispanic white women(8). 
 Most of CRC in pregnancy is an aggressive mucinous subtype(8), which have 
poorer prognosis(17),
 
but primary signet-cell carcinoma (SRCC) of the colon and 
rectum also represents a form of adenocarcinoma of the large intestine. Although its rare 
incidence of about less than 0,1% of cases of CRC in pregnancy, patients with SRCC 
are younger(14).  
  
Etiology and pathogenesis of CRC in pregnancy  
 CRC is one of the three most common types of cancer in women and can present 
in women of childbearing age, especially if there is a genetic predisposition(12).  
 In fact, environmental factors play a dominant role in the etiology of most CRC 
but inherited genetic factors are also significant in between 15% and 30% of cases. In 
about 5% of all cases, CRC is associated with a highly penetrant dominant or recessive 
inherited syndrome(18). When considering familial clustering of CRC and endometrial 
cancers, it is important to consider Lynch's syndrome (hereditary non‐polyposis 
colorectal cancer (HNPCC)), as a cause of cancer in pregnant women(19). It is an 
autossomic dominant inherited genetic disease(20), and thus multiple generations can 
develop CRC at an early age (mean, 45 years). Lynch syndrome is likely if a family 
history meets the Modified Amsterdam Criteria or revised Bethesda guidelines(11) 
 Familial adenomatous polyposis (FAP) is another inherited syndrome, 
responsible for <1% of all CRC cases. FAP is transmitted as an autosomal dominant 
trait, and is caused by truncating mutations in the (APC) adenomatosis polyposis coli 
gene. Recently, the MUTYH (mutY homologue (Escherichia coli)) gene has been 
identified as a further polyposis gene, displaying an autosomal recessive pattern of 
inheritance(18). 
 In what concerns to environmental factors, delayed childbearing and increased 
maternal age may lead to an increased incidence of CRC complicating pregnancy(6,21). 
 Some investigators demonstrated that 20 to 54% of colon cancers have estrogen 
receptors (Ers), whereas others have demonstrated progesterone receptors (PgRs), 
which may be stimulated by the estrogen and progesterone produced during pregnancy. 
The role of these hormones in the etiology and progression of CRC are limited and 
conflicting(12),  In fact, CRC pathogenesis and its relation to pregnancy is not well 
understood(8,12,17), and studies show that parity is not positively neither negatively 
associated with CRC(8). 
 When discovered during pregnancy, two-thirds of CCR in pregnant women tend 
to involve the rectum and sigmoid colon, unlike the general population where two-thirds 
arise from the extra pelvic colon(4,12–14,17). In fact, it is was reported that about 85% 
of CRC in pregnancy are below the peritoneal reflection(1,5,12,16). 
 
Prevention and screening  
 Advances in molecular basis of CRC include identifying the adenomatous 
polyposis coli (APC) gene, P
53
 gene, mismatch repair genes, and loss of allelic 
heterozygosity.(17) 
 Accordingly, as familial adenomatous polyposis (PAF) is a known risk factor for 
CRC during pregnancy, patients with family history of HNPCC should perform genetic 
testing(1,5). 
 When a patient develop CRC at a young age, it is important to consider the 
possibility of a hereditary cause, so we should confirm her family medical history in 
what concerns to cancers. Identification of the germline mutation in a Lynch syndrome 
family allows their inclusion in lifesaving cancer surveillance programs, which has been 
proven to reduce CRC mortality(22). Therefore, screening tests should be performed on 
tumour tissues to help determine the likelihood of this condition and microsatellite 
instability (MSI) analysis is the first approach to identify patients with Lynch syndrome. 
Germline testing for mismatch repair (MMR) gene alterations should be performed(11), 
as an autosomal dominant MMR deficiency leading to a tumour with MSI was assumed 
to be the primary mechanism for Lynch syndrome(23). In fact, germline mutations in 
the genes MLH1, MLH2, MSH6 and PMS2 can lead to the development of the 
syndrome, and heterozygosity for a mutation in one of these genes can result in 
increased susceptibility to cancer(11). 
 If Lynch syndrome had been suspected early diagnosis is essential. The 
American Cancer Society guidelines recommend colonoscopy beginning at an earlier 
age for high-risk individuals(11,24). Periodic examination by colonoscopy leads to the 
detection of CRC at an earlier stage, to a 63% reduction of the risk of CRC and to a 
significant reduction of the mortality associated(25). Annual colonoscopy programs 
performed at the age of 25 years in patients with families that have at least 3 relatives 
with a history of CRC or other HNPCC-related tumours  and in families with identified 
MMR defect(18). It is recommended a 3-year gap between colonoscopies because this 
time interval has proven effective for the detection of this condition(11). 
 When pregnant women with SRCC are analysed for microsatellite instability, 
studies confirm they represent about 30% of tumours. Moreover, mutations of K-ras and 
P
53
 gene have been reported in SRCC. Furthermore, replications of DNA are also 
suggested to be at least partly involved in carcinogenesis of SRCC(14). 
 Note down that genetic testing is only recommended for those with a family 
history suggestive of Lynch syndrome or other hereditary pattern, as most CRC are 
sporadic(11). 
 
Clinical features and Diagnosis 
 Diagnosis of CRC during pregnancy is challenging secondary to the difficulty in 
distinguishing pain of gynaecologic and GI origin(16,26), and the overlap in signs and 
symptoms of cancer and pregnancy(1–3,5,13,16). Consequently, usually there is a delay 
in diagnosis of CRC during pregnancy(4–7,10,12,26). Those signs and symptoms 
include nausea, vomiting, abdominal pain, weight loss, anemia, abdominal mass, rectal 
bleeding and altered bowel habits such as constipation.  
 Physiologic adaptations in pregnancy may also alter clinical presentations(12) 
so, high degree of suspicion if clinical features are suggestive of GI obstruction.(17)  
 However, sometimes there is no suspicion of CRC because its symptoms are 
absent(3) and foetal movements are normal(17).  In fact, several studies reported that 
CRC can develop during pregnancy without presenting symptoms(6,7,27). 
 When considering SRCC, symptoms usually develop later, leading to the non-
detection of cancers limited to mucosa and sub-mucosa(14). 
 Palpable abdominal mass is a uncommon finding(17) but a common problem 
can be excluded with a careful anorectal exam(1), yielding 67-84% accuracy in staging 
rectal carcinomas(14). 
 Intestinal obstructions are extremely rare in pregnant women
(2)
 but when 
present,  exploratory laparotomy must be commenced(28), as prompt operative 
intervention maximizes outcome for both foetus and mother(3). 
 Haemorrhoids or anal fissure, common causes of rectal bleeding, should be 
evaluated, and rectal examination should be performed when a patient presents with a 
complaint of pain and/or rectal bleeding(6,13). Persistent anorectal bleeding or rectal 
passage of tissue at the time of delivery is an ominous sigh of CRC cancer and should 
be investigated(12). 
 If a patient starts to lose weight while pregnant, she should be evaluated for 
maternal and foetal etiologies. Persistent nausea or vomiting, specially in the third 
trimester, should also be evaluated further(6). 
 Above all, it is crucial to consider complaints that are specific, severe or 
perseverate(3,4). 
 The diagnosis of CRC in a non-pregnant patient entails the tumour marker serum 
carcinoembryonic antigen (CEA), toraco-abdomino-pelvic imaging, and endoscopy 
with biopsy.  
 
 CEA 
 Evaluation of abnormal laboratory values is important to optimize patient 
diagnosis. CEA levels have been used during pregnancy for the diagnosis, monitoring 
and prognosis of CRC. Unfortunately, CEA levels tend to be normal or slightly elevated 
during pregnancy(14,16,17),
 
and are not considered a useful screening tool due to their 
low sensivity and specificity(12). 
 
 Colonoscopy 
 Colonoscopy is the gold standard to confirm diagnosis as it provides direct 
visualization, accurate determination of location, and the opportunity to obtain tumour 
tissue for pathological diagnosis of CRC(4,14). The American Society of 
Gastrointestinal Endoscopy indicate that an endoscopic intervention is safer than 
radiologically guided or surgical operations(1,5). However, pregnancy is a relative 
contraindication as this procedure may complicate pregnancy(4,12–14),  due to the risk 
of foetal exposure to potential teratogenic medications, uteroplacental insufficiency with 
maternal hypoxia or hypotention, and the risk for placental abruption with the 
mechanical pressure to the uterus(1,2,5,12). Accordingly, it is advised that strong 
indication should be present to proceed with an endoscopy, it should be delayed until 
second trimester where possible(1,5), the procedure time must be minimized and the 
lowest possible dose of sedative medications should be used(2). 
 With informed patient approval, the procedure may be performed with possible 
reduction in risk with the use of meperidine, because of its safer foetal profile, maternal 
oxygen administration, and gentle abdominal compression(12,14). 
 Because most cases of CRC during pregnancy are rectal carcinomas, if the 
lesion is confined to the distal colon, a flexible rectosigmoidoscopy (preferably without 
sedation) may be performed, as an alternative to colonoscopy(1,5,12,13). These one 
could be delayed in order to look for synchronous lesions. 
 
Staging 
 In the literature, most CRC are usually detected in its advanced stages, 
secondary to late diagnosis(3), during second or third trimester of pregnancy(6,12,13). 
A study that reviewed 41 patients with CRC during pregnancy observed that all patients 
had stage II or greater disease(12), while other refers that 60% are already diagnosed at 
stage III or IV(13). It corresponds to Dukes stage B or higher at presentation(4). 
 Staging is critical to ensure one is not dealing with advanced stage IV disease, as 
local management of colorectal malignancy would change considerably(2). 
 
 CT scan 
 Imaging evaluation during pregnancy is difficult since toraco-abdomino-pelvic 
CT scan, is relatively contraindicated in pregnancy. This procedure should be avoided 
particularly  in the first trimester, secondary to the foetal risk of radiation exposure 
teratogenicity and carcinogenicity(2–4,12–14,17). However, it is suggested that risk of 
adverse foetal effects is very low at doses of radiation used for diagnostic purposes, so 
CT of pelvis and abdomen can be performed with minimal risk(2,28). 
 
 Ultrasound  
 Ultrasound (US) evaluation is a reasonable alternative to CT. (17) It is especially 
useful for detection of hepatic metastases (2) (75% of sensitivity)(12,14) but, because of 
the gravid uterus, it has limited accuracy in detecting colon and rectal masses (3,12,13). 
Further diagnostics are frequently necessary when ultrasounds are negative.(3) 
 Transrectal ultrasound is helpful in late pregnancy to determine rectal cancer 
location and is more accurate in staging rectal cancer preoperatively, although it has not 
been proven to prolong survival.(17)  
 
 MRI 
 Similarly, magnetic resonance imaging (MRI) is relatively safe in pregnancy and 
should be considered after US indeterminate findings (28), but is good practice to avoid 
non-urgent MRI, particularly in the first trimester. (1,2) Moreover, it should be 
performed without contrast (3) because contrasts have not been approved for the foetus 
(12,13), being gadolinium known as teratogenic agent. (2) 
  
Treatment  
 Treatment during pregnancy is another challenging issue; Walsh et al have 
proposed an algorithm to manage CRC diagnosed during pregnancy based on the 
gestational age of the foetus, foetal lung maturity, cancer stage, need for adjuvant 
chemotherapy, and if elective or emergent surgery is indicated.(1,5,6,12,14,15)  
 The treatment goal is to implement therapy as soon as possible for the mother, 
(6,13) and balance this with delivery of the foetus with optimal for neonatal outcome. 
(1,12,13,16)  
 Treatment modalities may include surgery, radiation therapy and chemotherapy, 
depending on the stage of the cancer.(6) 
 
 Surgery 
 Surgery is the primary therapy for CRC outside of pregnancy (12,14) (8) In 
pregnant women with CRC it is recognized as safe and feasible (1) but its timing in a is 
a pivotal issue (2) so it should be considered on a case-by-case basis. 
 However, as the majority of CRC malignancies diagnosed in pregnancy occur 
below the peritoneal reflection, the level of technical difficulty associated with surgery 
is increased.(2) 
 If bowel obstruction develops during the pregnancy, a self-expanding metallic 
stent (SEMS) can be useful as it allows solving the acute condition, providing time to 
prepare the patient for surgery, thus reducing both post-surgical morbidity and 
mortality.(29)  
 Although no high-grade evidence exists regarding management of CRC in 
pregnancy, some clinical guidelines are reported in literature: 
 - If diagnosis is made in the first 20 weeks of pregnancy, treatment delay can 
lead to disease progression and compromise of mother's life. Therefore, the 
recommendation is discontinuation of the pregnancy, according mother's followed by 
early cancer treatment with surgical resection, as in non-pregnant patients. (2,13,14,16) 
However, controversia data regarding risk to the pregnancy with surgery, if imaging 
suggests that the tumour may be resected with clear margins, surgery might be an 
option. (2) In fact, low anterior or abdominoperineal resection has already been 
performed up to 20 weeks gestation without disturbance of the gravid uterus.(12) 
However, as CRC diagnosis is rarely made prior to 20 weeks of gestation, there is 
limited data on foetal outcome after surgical resection.(12) 
 - If colon cancer is diagnosed after 20 weeks gestation, surgery can be delayed 
until  delivery, in order to save the foetus (5,13,14,16), although endangering the patient 
with significant risk of disease progression (3), due to the pro-angiogenic state of 
pregnancy.(2) The ultimate goal is to achieve foetal lung maturation (8,16); 
nevertheless, delivery may vary from 28 to 32 weeks gestation, based on multispecialty 
team decision.(2,6,12) After that, treatment of CRC should take place as in a non-
pregnant patient.(2,14,15) 
 In both cases, the extent of resection is determined by tumour size, location, 
histologic grade and tumour extension into the colon wall and into adjacent tissue and 
organs.(14)  
  
 Chemotherapy 
 The need for chemotherapy depends upon the final histology of the tumour (2), 
being considered in stage II with high risk of recurrence (14) and stage III when nodal 
involvement is present.(8)  
 As a large portion of patients are diagnosed in advanced stages, is common that 
neoadjuvant chamoradiation before surgical resection is needed in rectal cancer. (13) 
Adjuvant chemotherapy has been shown to improve the survival rate by 5 to 10% for 
stage II or III CRC, (12) but evidence shows that in pregnant women with metastic 
rectal cancer it might spare the foetus, but not cure the mothers. (13)  
 Moreover, pelvic radiation is not recommended during organogenesis, in the 
first trimester of pregnancy (5,15,16), as it is associated with lethal damage to the 
foetus, with embryonic or foetal death, malformation, and growth retardation. (13,15) 
Although some studies reported that chemotherapy should be given only after delivery, 
other ones suggest that chemotherapy can be administered in the second or the third 
trimesters with dose maternal/foetal surveillence. (1,5,15)  The recommended 
therapeutic agent is 5-fluoruracil (5-FU), which is an inhibitor of DNA synthesis.(4) 
Although 5-FU is reported to be associated with low or no risk of adverse reproductive 
outcomes (9,10), some investigators have suggested a the possibility of spontaneous 
abortion (1,5) and teratogenicity associated with 5-FU (5,12,15,16)  
 Other new chemotherapeutic agents platinum-based like cisplatin and oxiliplatin 
are available but, according to the U. S. Food and Drug Administration, they are not 
recommended during pregnancy. (12,15,16) 
 The previous reasons could explain why women with pregnancy-associated 
CRC were less likely to undergo chemotherapy, in comparison to non-pregnant women 
in the same condition.(8) 
 It is also important to report that, considering Lynch syndrome, tumours with 
MSI were more responsive to adjuvant chemotherapy than tumours without MSI.(11) 
 
 Radiotherapy 
 Adjuvant radiotherapy is indicated for Duke's B2 and C rectal cancers (12), T4 
lesions adherent to the pelvic structure and in patients with close or positive surgical 
margins.(8,14) Nevertheless, radiation treatment of the pelvis is contraindicated during 
pregnancy (2,5,15) and is usually delayed until after delivery (12,16) as it has been 
implicated in sexual and gonadal dysfunction, foetal growth restriction or spontaneous 
miscarriage. (9) 
  
 Biological therapies  
 Biological agents like bevacizumab, cetuximab or panitumumab provide 
relatively modest survival increase in addition to standard chemotherapy, withholding 
their use until delivery would not be likely to prevent curative treatment.(10) 
 
 In stage IV disease, palliative management should be performed and emphasis 
should be to lengthen the progression-free and overall survival in the unresecable 
metastic CRC. (14) 
(12)  
 
Vaginal delivery vs cesarean 
 The delivery mode is controversial as cancer per si is not an indication to 
perform a cesarean section. (5,16) However studies show that cesarean section is more 
practiced in women with pregnancy associated with CRC.(8) 
 Outside the normal obstetrical indications for cesarean section, indications for an 
operative delivery in CRC patients include a tumour along the anterior rectal wall, 
secondary to increased risk of bleeding with vaginal birth pressure or birth canal 
obstruction by tumour.(12) Cesarean also can be considered if resection of the CRC at 
the time of delivery will be performed.(5,14,16) 
 There has been a recent move toward vaginal delivery for women with rectal 
carcinoma, even with an unripe cervix requiring a cervical ripening agent. (12)  
 
Complications 
 The delay in diagnosis lead to an increase of complications as the uterus, cervix 
and adnexa share the same visceral innervation as the lower ileum, sigmoid colon, and 
rectum. (26) About 25% of pregnant women with CRC will have ovarian metastases. 
(12,14,16) If tumor resection is performed during pregnancy, prophylactic ovarian 
removal may be deferred secondary to the possible risk for a spontaneous abortion, 
especially in the first trimester. Bilateral oophorotomy is performed during pregnancy, 
if evidence of invasion. (12,16) 
 The liver is the most common site for synchronous metastases (14) but there are 
no reports of liver resection for CRC liver metastases during pregnancy.(10,16)  
 Colon obstruction, perforation, and metastasis are more frequent in pregnant 
women with CRC than the average population, (17) possibly due to the 
immunosuppressive state of pregnancy.(12) 
 
Foetal risk 
 Its reported that higher rates of preterm labour and major puerperal infections 
are noted in women with pregnancy associated with CRC, as this malignant condition 
prone to infections that may be sub-clinical before delivery. (8) This could be explained 
by the malignancy-related immune suppression, as CRC initiates an inflammatory 
reaction that consequently starts the preterm labour cascade secondarily to the close 
proximity to the uterus.(8) 
 Despite high rates of preterm delivery, some studies reported an absence of 
adverse foetal outcomes (5,8), while others refer that only 78% of foetus from women 
with CRC survived.(5) Conversely, there is agreement that the risk of foetal malignancy 
is rarely observed, even when the disease is in an advanced stage with widespread 
metastasis. (5,17) However, metastasis to the placenta was reported once in maternal 
colorectal malignancy.  
 Even though a complete evaluation of the placenta is recommended, there is no 
evidence to support periodic follow-up of the baby.(5) 
 
Prognosis 
 Pregnant women with CRC tend to have poor outcome, which usually includes 
widespread metastasis (5), mainly secondary to delayed diagnosis. (4,6,8,12,16). 
Moreover, when considering SRCC, it is more likely to experience lymph node 
metastasis, have an aggressive clinical course and poor prognosis. (14) 
 Previous studies reported that patients with CCR regarding Lynch syndrome 
with MSI survived longer than patients with non-MSI tumours did; accordingly, the 
former ones showed lower mortality rates when stratified by tumour stage, including 
patients with stage IV cancer.(11) Hence, the detection of MSI in a CCR is a positive 
prognostic factor, particularly among young patients.(11,20)  
  
 Most of all, it is important to notice that women that are not surgically treated 
died at a rate that was 4.2 times that of women who undergo surgical treatment.(8) 
 When comparing pregnant to non-pregnant women with CRC, 5 year cancer 
survival is the same (12) Women with colon cancer died at a faster rate than those with 
rectal or anal cancer, even though it is reported that pregnancy was not associated with a 
significant difference in survival between these two groups. (5,8) 
 
 
Discussion 
 After this review it appears that there is still much to be clarified, especially in 
the treatment area. Despite a rising incidence of CRC in pregnancy due to, at least in 
part, more women falling pregnant at an advanced maternal age, only few studies were 
performed about this issue. Moreover, most of those have not been completed due to 
ethical reasons, so there is information evaluating new therapies.   
 CRC in pregnancy is rare but its incidence is increasing not only because more 
women are postponing pregnancy until later in life but also because there is an increased 
risk for this cancer in women with more than 40 years old.(5,10) 
 This cancer in gravidity is not well understood but, as genetic alterations 
contribute to the susceptibility to CRC it is important to offer genetic counselling, 
especially when other CRC is recognised in the family history.(8) 
 As abdominal symptoms are common in pregnancy and CRC can mimic them, 
they are overlooked. (6,13,16) Thus, differential diagnosis should include the patient's 
history, physical examination, laboratory data, and radiologic findings that may assist in 
identifying the diagnosis (12); an appropriate work-up may result in prompt evaluation, 
detection and appropriate interventions to treat CRC (6,12,28) as early diagnosis 
improves survival and treatment outcomes.(1,2,6)  In the era of possible cancer 
treatment in pregnancy, patient's chance of survival should not be diminished by 
delayed diagnosis.(7) 
 Further management is individualized and dependent on various factors 
including maternal age, patient's desire for future fertility, gestational age at diagnosis, 
and cancer stage.(12) However, pregnancy can limit and contraindicate the utilization of 
standard diagnostic and therapeutic tools due to a gravid uterus and a potentially 
vulnerable foetus, which can hamper the liberal use of colonoscopy and CT. (1,13) 
Physical evaluation plays an essential role, specially the evaluation of liver size and a 
rectal examination to screen for masses. (6) Abdominal US is first recommended, but its 
use is limited due to the patient's change in body habitus (28). MRI or CT may be used 
if necessary, although CT is not desirable due to foetal irradiation (28). Laparoscopy, 
EGD, and sigmoidoscopy can be performed during pregnancy, when strongly 
indicated.(12) 
 Most medications appear to be relatively safe to the foetus and can be used when 
benefits to the mother outweigh potential foetal risks. (12) 
 Surgery is the main stay of treatment but its indications differ if CRC diagnostic 
occurs in the first half or in the second half of pregnancy. Secondarily, in adjuvant and 
neoadjuvant settings, RT and CRT have significant role in accordance to the site of 
tumor.(14) However, there is few data suggest association between pregnancy outcome 
and treatment with chemotherapeutic agents, used in treatment of CRC. (12)  Therefore, 
it may still difficult to provide precise guidance to patients about long-term effects of 
this treatment. (9,16) 
  
 
Conclusion  
 The coexistence of malignant tumour and pregnancy is a state of simultaneous 
occurrence of two completely contradictory phenomena – the development of a new life 
and a life-threatening terminal illness. In fact, CRC is an aggressive cancer that is rarely 
found during pregnancy, but when it appears it is expected poor outcome, as its usually 
diagnosed in late stages. (6,12,13)  
 Because there are no absolute guidelines, it is associated with diagnostic and 
therapeutic challenges,(10,13) as gravidity requires further quick and adequate 
diagnosis. (3)  
 There is necessary further investigations about diagnostic and treatment 
modalities with reduced foetal side effects, in order to diminish its incidence and 
mortality rate.(1) Follow-up of the infants in later childhood and adolescence as the 
central nervous system continue to develop,  with additional reporting of cases, is 
needed to establish the safety of chemotherapeutic treatment of CRC during 
pregnancy.(16)  
 In fact, treatment during pregnancy varies widely and poses significant legal, 
ethical, religious, emotional and scientific challenges; therapy should be individualized 
and defined by a multidisciplinary team (12)  that considers not only through patient 
counselling,  but also the best management for both the patient and her foetus.  (2) All 
the professionals who look after such a special patient should inform her considering the 
most current and reliable knowledge, providing her a multidisciplinary care, and 
understanding the complexity of coexistence of cancer and pregnancy. The patient 
should have the opportunity to decide about the fate of her pregnancy and it should not 
be affected by the moral beliefs of the doctor; the final decision concerns only to the 
patient(1,21,30,31) 
  Above all, the treatment strategy for CRC should be no different for pregnant 
and non-pregnant patients in terms of the aim, which is potential curative treatment of 
the disease, but should always consider the patient's conscious decision on pregnancy 
further management. 
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